Day One

Coffee & Tea Served

• Panelists will examine the state of the radiopharmaceutical supply chain in 2026: where infrastructure investment is landing, where the workforce deficit is most acute, and how the shift in isotope preferences – from the established beta emitters toward alphas and emerging candidates – is creating new pressure across every manufacturing echelon
• Discussing the compounding risks that arise as programs progress into Phase II/III, where reliance on limited isotope supply, third-party manufacturing, logistics, and fragmented coordination from CDMO through to bedside must be managed in parallel to avoid disruption to clinical delivery
• Discuss what ‘commercial readiness’ actually means for radiopharmaceuticals and why the industry’s collective definition has to evolve beyond approval to include reliable, scalable, and distributed supply at the patient level

• Exploring emerging production pathways (thorium extraction, accelerator-based methods, reactor routes) and assessing their scalability and commercial viability
• Strategizing long-term supply agreements and partnership models to secure access to Ac-225 in a competitive and supply-constrained environment
• Managing quality and regulatory considerations associated with Ac-225 production, including handling impurities such as Ac-227 and downstream QC implications

This informal session provides the perfect opportunity to connect with your industry colleagues,

from CMC & MSAT leaders to supply chain, operations, and logistics experts. Instigate useful

introductions to build upon for the rest of the conference forming valuable connections.

• Evaluating current and emerging isotope supply landscapes across alpha and beta emitters
• Comparing production routes (reactor, cyclotron, generator-based) and understanding implications for scalability and reliability
• Designing multi-supplier models (primary, secondary, tertiary) to safeguard continuity of clinical supply

• Transitioning from low-volume, flexible production to high-throughput, standardized manufacturing systems
• Scaling batch sizes while maintaining product quality, consistency, and regulatory compliance
• Identifying infrastructure, equipment, and workforce requirements for late-stage trials
• Mitigating risks associated with rapid scale-up and increasing demand

This session will feature an expert-delivered presentation, before opening to a facilitated audience discussion

• Coordinating timelines across equipment readiness, process validation, and regulatory requirements
• Managing communication, timelines, and performance metrics to ensure reliable delivery
• Navigating challenges associated with multi-client CDMO environments and competing priorities

Overview of Radio-DARPin drug product development with emphasis on manufacturing as a critical enabler for clinical progression

• Strategies for robust process development to ensure manufacturing consistency and reliability
• Definition and alignment of early development milestones to support first in human studies
• Design of a phase appropriate and resilient supply chain tailored to the evolving needs of clinical development

Connect with peers in a relaxed atmosphere and continue to forge new and existing relationships while exploring the latest advancements in the development of radiopharmaceutical therapies.

To submit a poster, please contact info@hansonwade.com

Panellists will examine how automating synthesis processes can improve consistency, reproducibility, and throughput, while supporting the scale-up required for late-stage and commercial manufacturing

• Exploring different approaches to transition from manual to semi-automated to fully automated systems across dispensing, quality control, and packaging
• Panelists share their operational considerations when integrating automated systems into existing manufacturing environments

• Mapping how data currently moves between CDMOs, logistics providers, sponsors, and sites, and identifying where fragmentation creates delays or miscommunication
• Integrating scheduling, shipment tracking, and site readiness data to improve alignment between drug availability and patient treatment windows
• Reducing manual interventions and communication gaps by creating clearer digital workflows across the supply network